New patient guidelines for heart devices

A series of new guidelines for cardiac specialists has been developed to determine when heart failure patients should receive a mechanical heart-pumping device.

"The new guidelines will likely affect who is referred for a mechanical circulatory support device, and how early in the process a physician would consider implanting a left ," says Jeffrey A. Morgan, M.D., associate director of Mechanical Circulatory Support at Henry Ford Hospital. "These guidelines have the ability to change clinical practice patterns for patients with advanced ."

Dr. Morgan will present the guidelines Saturday, April 16 at the International Society of Heart and Lung Transplantation (ISHLT) annual meeting in San Diego.

The left ventricular assist device (LVAD) is a battery-operated pumping device, surgically implanted to help a weakened blood.

Last year, approximately 2500 LVADs were implanted nationally, which is used chiefly for patients waiting for a heart transplant due to the chronic donor shortage. In other cases, it is used for long-term support in patients who are not eligible for a .

Dr. Morgan played a leadership role in the formation of the ISHLT's Mechanical Circulatory Support Council that authored the guidelines, due to the high-quality, high-volume LVAD implant program at Henry Ford. The program has a growing national reputation in clinical, academic and research areas.

add to favorites email to friend print save as pdf

Related Stories

Study: Fewer infections with new heart-pump implant

May 27, 2010

A state-of-the-art heart pump recently approved for use in end-stage cardiac patients has a significantly lower risk for infection than an earlier model of the device, according to researchers at Henry Ford Hospital in Detroit.

Recommended for you

Growing a blood vessel in a week

4 hours ago

The technology for creating new tissues from stem cells has taken a giant leap forward. Three tablespoons of blood are all that is needed to grow a brand new blood vessel in just seven days. This is shown ...

Testing time for stem cells

7 hours ago

DefiniGEN is one of the first commercial opportunities to arise from Cambridge's expertise in stem cell research. Here, we look at some of the fundamental research that enables it to supply liver and pancreatic ...

Team finds key signaling pathway in cause of preeclampsia

Oct 23, 2014

A team of researchers led by a Wayne State University School of Medicine associate professor of obstetrics and gynecology has published findings that provide novel insight into the cause of preeclampsia, the leading cause ...

Rapid test to diagnose severe sepsis

Oct 23, 2014

A new test, developed by University of British Columbia researchers, could help physicians predict within an hour if a patient will develop severe sepsis so they can begin treatment immediately.

User comments